ArticleFrontiers in oncology2026
ATF4 and SLC7A11 as biomarkers predicting progression and prognosis in lung adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer, yet reliable biomarkers for stratifying early-stage patients at high risk of progression and poor prognosis remain limited. Methods: We enrolled 168 LUAD patients who underwent surgery at The Fourth Hospital of Hebei Medical University. ATF4 and SLC7A11 expressions were assessed by immunohistochemistry. Associations with clinicopathological features were evaluated by χ²/Fisher's exact tests; univariate and multivariate Cox regression analyses of overall survival (OS) and metastasis-free survival (MFS) were performed, and model discrimination was quantified by the concordance index (C-index). Results: ATF4 was nuclear-positive in 55.4% of tumors, and SLC7A11 was cytoplasmic-positive in 59.5% of tumors. Neither ATF4 nor SLC7A11 was positively expressed in the stromal cells. The expression of ATF4 and SLC7A11 in tissues with pathological necrosis was enhanced. Both ATF4 and SLC7A11 correlated with aggressive features (more aggressive pathological subtypes with malignant potential, advanced clinical stage, lymph node metastasis, poor differentiation, pleural invasion, and pathological necrosis). ATF4 expression was also associated with lymphatic/vascular invasion. ATF4 (HR = 1.533, 95% CI, 1.040-2.259; Conclusion: ATF4/SLC7A11 are clinically useful prognostic biomarkers in LUAD. Either ATF4- or SLC7A11-positive expression appears to yield enhanced predictive value and may help identify high-risk patients for intensified surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.